Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
14 juil. 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
14 mai 2021 13h35 HE
|
Qualigen Therapeutics, Inc.
Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT. Revenues Increased 30 Percent to $1.9 Million Compared to $1.5 Million in the Same Quarter of the Previous YearOn Track to File an IND...
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
11 mai 2020 08h00 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the...